Elicio Therapeutics (ELTX) investor relations material

Corporate and pipeline overview

• Focus on immunotherapeutics using the AMP platform to enhance lymphatic targeting and immune response against cancers, with broad applicability across cancer types.

• Lead program ELI-002 targets mutated KRAS, present in 25% of solid tumors, with phase I data in pancreatic and colorectal cancer and ongoing phase II in adjuvant pancreatic cancer.

• Pipeline includes assets targeting other high-frequency mutations such as BRAF and P53, with early-stage programs in development.

• AMP platform aims to overcome historical challenges in immunotherapy by improving antitumor immune responses and enabling off-the-shelf solutions.

• Personalized tumor immunity observed through antigen spreading, expanding immune response beyond targeted mutations.

Clinical trial results and differentiation

• Phase I studies in pancreatic and colorectal cancer showed robust immune responses, with T-cell activity strongly correlated to clinical benefit.

• ELI-002 demonstrated favorable relapse-free and overall survival compared to historical controls, with 100% of patients generating mutant KRAS-specific T-cells.

• 7-peptide formulation covers a broader range of KRAS mutations, maintaining strong safety and tolerability with no dose-limiting toxicities.

• Antigen spreading led to 70% of patients generating immune responses against additional tumor mutations.

Ongoing and future studies

• Phase II trial in adjuvant pancreatic cancer is randomized, focusing on disease-free survival as the primary endpoint, with final analysis expected mid-2026.

• Interim analysis confirmed safety and preliminary activity, supporting progression to phase III planning in alignment with FDA guidance.

• Secondary endpoints show 99% of patients generating KRAS-specific T-cell responses, with 80% exceeding the threshold previously linked to clinical benefit.

• Antigen spreading observed in 87% of patients in phase II, supporting broad applicability.